Literature DB >> 14723616

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

R J Cox1, K A Brokstad, P Ogra.   

Abstract

Influenza virus is a globally important respiratory pathogen which causes a high degree of morbidity and mortality annually. The virus is continuously undergoing antigenic change and thus bypasses the host's acquired immunity to influenza. Despite the improvement in antiviral therapy during the last decade, vaccination is still the most effective method of prophylaxis. Vaccination induces a good degree of protection (60-90% efficacy) and is well tolerated by the recipient. For those at risk of complications from influenza, annual vaccination is recommended due to the antigenic changes in circulating strains. However, there is still room for improvement in vaccine efficacy, long-lasting effect, ease of administration and compliance rates. The mucosal tissues of the respiratory tract are the main portal entry of influenza, and the mucosal immune system provides the first line of defence against infection. Secretory immunoglobulin A (SIgA) and IgM are the major neutralizing antibodies directed against mucosal pathogens. These antibodies work to prevent pathogen entry and can function intracellularly to inhibit replication of virus. This review describes influenza virus infection, epidemiology, clinical presentation and immune system response, particularly as it pertains to mucosal immunity and vaccine use. Specifically, this review provides an update of the current status on influenza vaccination and concentrates on the two main types of influenza vaccines currently in use, namely the cold-adapted vaccine (CAV) given intranasally/orally, and the inactivated vaccine (IV) delivered subcutanously or intramuscularly. The commercially available trivalent IV (TIV) elicits good serum antibody responses but induces poorly mucosal IgA antibody and cell-mediated immunity. In contrast, the CAV may elicit a long-lasting, broader immune (humoral and cellular) response, which more closely resembles natural immunity. The immune response induced by these two vaccines will be compared in this review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14723616     DOI: 10.1111/j.0300-9475.2004.01382.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  205 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

2.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

3.  Airborne transmission of influenza: implications for control in healthcare and community settings.

Authors:  Benjamin J Cowling
Journal:  Clin Infect Dis       Date:  2012-03-29       Impact factor: 9.079

4.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

5.  A replication-incompetent PB2-knockout influenza A virus vaccine vector.

Authors:  Sylvia T Victor; Shinji Watanabe; Hiroaki Katsura; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

6.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

7.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

Review 9.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

Authors:  C R Baskin; H Bielefeldt-Ohmann; A García-Sastre; T M Tumpey; N Van Hoeven; V S Carter; M J Thomas; S Proll; A Solórzano; R Billharz; J L Fornek; S Thomas; C-H Chen; E A Clark; Kaja Murali-Krishna; M G Katze
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.